We supply Vismodegib (GDC-0449)

We're proud to offer Vismodegib(GDC-0449), a largely effective drug for the treatment of advanced rudimentary cell melanoma. This drug works by inhibiting the Hedgehog signaling pathway, which is hyperactive in the development of utmost rudimentary cell lymphomas . it has been clinically proven to shrink or exclude excrescences in a significant chance of cases, and is generally well-tolerated.However, consider Vismodegib as a implicit treatment option, If you or a loved one is suffering from advanced rudimentary cell melanoma. Our force is of the loftiest quality and available for purchase now.

What's Vismodegib  ?

Vismodegib, also known as GDC-0449, is a drug used to treat advanced rudimentary cell melanoma( BCC), a type of skin cancer. It works by inhibiting the hedgehog signaling pathway, which plays a major part in the growth and development of BCC excrescences. Vismodegib specifically blocks a protein called smoothened, which is involved in cranking the hedgehog pathway. This drug is taken orally in the form of a capsule and is generally specified for cases with locally advanced BCC that can not be treated with surgery or radiation, or for those with metastatic BCC that has spread to other corridor of the body. Treatment with it can reduce excrescence size and ameliorate overall survival rates for cases with advanced BCC. Its common side goods include muscle cramps, hair loss, fatigue, and loss of taste. It may also beget birth blights in pregnant women, so it's important to use effective contraception while taking this drug and for up to 7 months after stopping treatment.

it is generally specified by a dermatologist or oncologist and may be used in combination with other treatments similar as surgery or radiation. It's important to follow the lozenge and timing instructions handed by your healthcare provider and to report any side goods or enterprises instantly. it has been shown to be effective in treating advanced BCC and offers a new treatment option for cases with this delicate- to- treat cancer.

Basic Information

Product Name: Vismodegib; GDC-0449

CAS: 879085-55-9

MF:C19H14Cl2N2O3S

MW:421.3

EINECS:806-752-3

MDL No.:MFCD12407408

Structural formula:

Origin: China

Application: Anti tumor; anti-cancer

Delivery Time: in stock

Technical Specification

Package: 10g; 100g; 500g; 1kg or according to your demands

Storage: Preserve in tight,light-resistant containers in a cool place

Shelf Life: 24 months

Purpose

Used for the treatment of locally progressive or metastatic rudimentary cell melanoma in grown-ups witnessing surgery or radiotherapy for postoperative rush or discomfort; rudimentary cell melanoma( BCC) is one of the most common skin cancers, forming from the face subcaste of the skin, and cases don't feel pain. The threat of skin conditions is loftiest for those who are constantly exposed to sun or ultraviolet radiation. The R&D and launch of Vismodegib have brought good news to BCC cases. Its clinical part is important and its target request is huge, and it'll grow into a" giant lemon" position(> 1 billion US bones) medicine in the future.

Mechanism of action

GDC-0449 has a new medium of action and is a picky Hedgehog signaling pathway asset. Although the Hedgehog signaling pathway is active in early life and plays an important nonsupervisory part in mortal growth and development, it isn't active in grown-ups. The vast maturity(> 90) of cases with rudimentary cell melanoma parade inordinate exertion in the Hedgehog signaling pathway, which is considered a abecedarian molecular motorist of rudimentary cell melanoma. It acts as a competitive cyclopamine antagonist and acts on the transmembrane G protein coupled receptor protein( Smoothened) in the Hedgehog signaling pathway. It can block the expression of excrescence nonsupervisory genes related to the Hedgehog signaling pathway by inhibiting SMO receptors to keep recap factors GLT- 1 and GLT- 2 inactive.

Synthetic route

Clinical trial process

Vismodegib(GDC-0449) is the first progressive rudimentary cell melanoma treatment medicine approved by the US FDA to date. The FDA in the United States made its blessing decision for GDC 0449 primarily grounded on phase II transnational, multicenter, single group, two cohort, open marker clinical trial data from a study codenamed SHH4476g. This trial included a aggregate of 96 cases with locally progressive( 71 cases) and metastatic( 33 cases) rudimentary cell melanoma, all of whom entered treatment with 150mg/ d of GDC0449 until complaint progression or inferior toxin passed. The primary endpoint was the objective response rate estimated by an independent expert panel. The exploration results showed that the objective response rates of cases with locally progressive and metastatic rudimentary cell melanoma treated with it were 43% and 33%, independently, with a median response time of7.6 months.

Side reaction

Its most common side goods treatment include muscle spasms, hair loss, taste changes or loss, weight loss, fatigue, nausea, diarrhea, dropped appetite, constipation, puking, and common pain. it has teratogenicity, and cases of travail age must take contraceptive measures during the treatment period with this drug.

Payment Term

Why Choose Xi'an Yihui?

Customer feedback

Xi'an Yihui certificates

Xi'an Yihui Factory & Warehouse

Where to buy?

In summary, as a professional Vismodegib(GDC-0449)manufacturer, we have advanced technology, scale advantage, the best quality, rich production experience, and excellent services. These advantages will make it stand out in the market competition and win more customer trust and support. if you need GDC-0449, pls feel free to contact us any time. we will reply you asap.

our contact information:

E-mail: sales@yihuipharm.com
Tel: 0086-29-89695240
WeChat or WhatsApp: 0086-17792415937